- Home
- REI vs MNPR Comparison
REI vs MNPR Comparison
Compare REI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- MNPR
- Stock Information
- Founded
- REI 2004
- MNPR 2014
- Country
- REI United States
- MNPR United States
- Employees
- REI N/A
- MNPR N/A
- Industry
- REI Oil & Gas Production
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- MNPR Health Care
- Exchange
- REI Nasdaq
- MNPR Nasdaq
- Market Cap
- REI 241.9M
- MNPR 249.5M
- IPO Year
- REI N/A
- MNPR 2019
- Fundamental
- Price
- REI $0.81
- MNPR $32.86
- Analyst Decision
- REI
- MNPR Strong Buy
- Analyst Count
- REI 0
- MNPR 5
- Target Price
- REI N/A
- MNPR $59.50
- AVG Volume (30 Days)
- REI 4.3M
- MNPR 24.2K
- Earning Date
- REI 08-05-2025
- MNPR 08-08-2025
- Dividend Yield
- REI N/A
- MNPR N/A
- EPS Growth
- REI N/A
- MNPR N/A
- EPS
- REI 0.36
- MNPR N/A
- Revenue
- REI $335,642,768.00
- MNPR N/A
- Revenue This Year
- REI $2.59
- MNPR N/A
- Revenue Next Year
- REI $17.45
- MNPR N/A
- P/E Ratio
- REI $2.27
- MNPR N/A
- Revenue Growth
- REI N/A
- MNPR N/A
- 52 Week Low
- REI $0.72
- MNPR $1.72
- 52 Week High
- REI $2.06
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- REI 47.63
- MNPR 42.95
- Support Level
- REI $0.81
- MNPR $33.00
- Resistance Level
- REI $0.94
- MNPR $35.01
- Average True Range (ATR)
- REI 0.06
- MNPR 2.68
- MACD
- REI 0.01
- MNPR 0.00
- Stochastic Oscillator
- REI 28.11
- MNPR 32.27
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.